November 29, 2016 - By Richard Conner · 0 Comments
The stock of CARDAX INCORPORATED (OTCMKTS:CDXI) registered an increase of 1828.57% in short interest. CDXI’s total short interest was 54,000 shares in November as published by FINRA. Its up 1828.57% from 2,800 shares, reported previously. With 62,000 shares average volume, it will take short sellers 1 days to cover their CDXI’s short positions. The stock decreased 12.50% or $0.01 on November 28, hitting $0.07. About 20,000 shares traded hands or 8.41% up from the average. Cardax Inc (OTCMKTS:CDXI) has risen 37.25% since April 26, 2016 and is uptrending. It has outperformed by 32.00% the S&P500.
Cardax, Inc. is a life sciences company. The company has a market cap of $5.83 million. The Firm develops consumer health and pharmaceutical technologies. It currently has negative earnings. It is a development-stage life sciences company.
Cardax, Inc., incorporated on January 30, 2012, is a life sciences company. The Firm develops consumer health and pharmaceutical technologies. The Firm has not produced and commercialized any products or generated any revenues from its life sciences business.
More notable recent Cardax Inc (OTCMKTS:CDXI) news were published by: Streetinsider.com which released: “Cardax, Inc. (CDXI) Enters $5B Equity Purchase Agreement” on July 18, 2016, also Bizjournals.com with their article: “Hawaii’s Cardax Inc. synthetic astaxanthin found to be twice as effective as …” published on July 31, 2015, Seekingalpha.com published: “Cardax Pharma: Addressing The Growing Inflammation Market With Nature’s Answer” on May 16, 2014. More interesting news about Cardax Inc (OTCMKTS:CDXI) were released by: Businesswire.com and their article: “Cardax Launches First Product ZanthoSynâ„¢” published on August 24, 2016 as well as Bizjournals.com‘s news article titled: “Cardax Pharmaceuticals becomes Hawaii’s 16th publicly-traded company” with publication date: February 07, 2014.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Richard Conner